A new preprint (June 2025) shows that microclots formed during COVID-19 can obstruct capillaries and impair microcirculation.
And remarkably, an earlier peer-reviewed study reached the same conclusion - by a completely different method. 🧵
In the new study by Kell, Pretorius et al., SARS-CoV-2 is associated with abnormal blood clotting that produces fibrinaloid microclots - clots containing amyloid (!) fibrin that are resistant to fibrinolysis (breakdown). preprints.org/manuscript/202…
These microclots are made of amyloid-type fibrin - a misfolded version that resists not only natural fibrinolysis, but also standard clot-busting drugs.
In other words: your body can’t easily remove them. Neither can your meds.
Using laser Doppler and laser speckle imaging (LDI/LSI), the researchers found:
elevated blood pressure
reduced capillary blood flow
Consistent with capillary obstruction and rarefaction.
This suggests high blood pressure is an effect, not the cause!
Now compare this with a prior peer-reviewed study (Jalal et al., Scientific Reports, 2025):
Researchers trained an AI model (EfficientNet) to detect abnormalities in nailfold capillary images: dilated, hemorrhagic, and disorganized vessels nature.com/articles/s4159…
The AI model (CE-NFCNet) achieved perfect accuracy in distinguishing healthy vs abnormal capillaries- even in noisy images (eg low contrast, dark skin, glare).
Another line of evidence pointing to microvascular damage.
Two different technologies - one functional (blood flow), one structural (capillary morphology) - arrive at the same insight:
COVID-19 leaves a lasting mark on the microvasculature, even in mild or asymptomatic cases.
On the left: healthy nailfold capillaries.
On the right: capillaries one year after COVID.
The person on the right was never diagnosed with Long COVID!
Below:
A healthy individual
B asymptomatic COVID
C & D two patients with Long COVID
Different clinical stories, but a shared vascular footprint.
What we see in the skin (nailfold) is a window into systemic microcirculation.
If the capillaries are damaged here, it’s highly likely that similar damage exists in the lungs, brain, heart, kidneys - we just can’t visualize it as easily.
These changes are:
not rare
not limited to severe COVID
not always reversible
Capillary networks do not regenerate easily - if at all.
In future waves of SARS-CoV-2 - wearing a respirator isn’t extreme.
It’s one of the few ways to protect a system that doesn’t repair itself well - your microcirculation.
And while we're connecting dots - let’s go back to 2020.
Already then, a pediatric study showed that most children infected with SARS-CoV-2 had lab evidence of endothelial injury, even with mild or no symptoms.
In this Blood Advances study from CHOP (Children’s Hospital of Philadelphia),
86% of children met diagnostic criteria for microangiopathy (TMA) - based on elevated sC5b‑9,
a marker of complement-mediated capillary damage.
Even in regular COVID cases.
Worth noting: the 2020 CHOP study was done in hospitalized kids (COVID or MIS-C).
But importantly, many had no obvious symptoms of vascular injury - yet still showed strong lab signs (↑sC5b‑9).
Suggests subclinical damage may be broader than we think.
Later studies confirmed this:
increased circulating endothelial cells (CECs)
elevated MCP-1, VEGF-A, IL-8
= signs of ongoing endothelial activation and vascular inflammation - even in pediatric COVID.
All of this helps explain why:
breathlessness can linger
microvascular imaging looks abnormal
cognitive function dips
even when “routine tests” come back normal.
We're not just fighting a virus - but its systemic footprint.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
We are still trying to place Long COVID into a biologically coherent framework.
This study is interesting because immune activation, antiviral signaling, metabolism, mitochondria, cell survival do not appear as separate findings - but as parts of one connected system🧵
A possible axis is this
something keeps innate immunity on alert - immune cells produce inflammatory signals - their metabolism shifts - mitochondria come under stress - stressed mitochondria can further amplify immune activation.
That is a loop, not a list.
The study compared 50 people with Long COVID with 50 recovered controls around 10 months after SARS-CoV-2.
Both groups had been infected. The key difference was whether symptoms persisted.
Even in the Omicron era, SARS-CoV-2 was linked to a several-fold increase in serious thromboembolic and cardiovascular events - and that risk persisted for months after infection🧵
A new European preprint cohort study looked at ~780,000 people with COVID-19 and 7.6 million pre-pandemic controls across three health databases in the UK, the Netherlands and Spain.
The main finding is hard to ignore.
In the first 30 days after infection, the standardized incidence of venous thromboembolism was about 3.6-4.1 times higher than expected!
A new narrative review by Kell, Zhao & Pretorius looks at Long COVID through the lens of microcirculation. The idea that persistent fibrinaloid microclots may contribute to impaired blood flow in the smallest vessels.🧵
This is not a systematic review or meta-analysis. It is better read as a broad mechanistic argument. A way to connect existing findings on inflammation, endothelial dysfunction, coagulation, fibrinolysis and Long COVID symptoms.
The central idea is that, in some inflammatory states, blood may form abnormal microclots containing fibrin and other proteins in an amyloid-like form. Fibrinaloid microclots.
A new warning study that deserves attention.
SARS-CoV-2 leaves a long-term endothelial and metabolic footprint in the blood months after infection - even in people without obvious Long COVID symptoms.
And that matters🧵
Researchers followed 262 adults in Germany and measured blood biomarkers about 37 weeks after infection - roughly 9 months later.
People who had previously had COVID showed higher markers of endothelial dysfunction and tissue stress, including soluble thrombomodulin and LDH, compared with never-infected controls.
A new long COVID study found that standard autoimmune blood tests often looked normal. But when researchers tested patients blood directly against heart and blood vessel tissue, they found persistent immune reactivity - especially involving vascular tissue.🧵
The study found tissue-specific autoreactivity in many long COVID patients - especially against vascular tissue - while standard ANA screening often looked normal.
They found tissue-specific autoreactivity in 83% of long COVID patients vs 53% of pre-pandemic controls.
The clearest statistically significant difference was against vascular tissue.
34% in long COVID vs 8% in controls.
SARS-CoV-2/spike RBD may act as a potential modifier of glioma progression in biologically susceptible cells. An interesting mechanistic study that raises a warning signal.🧵
Methods first.
This study combines single-cell RNA, bulk RNA-seq, spatial transcriptomics, survival analysis, pathway/enrichment analysis, and in vitro experiments on primary glioblastoma cells.
The authors looked at genes and proteins linked to SARS-CoV-2 cell entry
ACE2, BSG/CD147, NRP1, TMPRSS2, FURIN, FCGR1A, HSPG2.
These factors were mapped across healthy brain cells, COVID-19 brain samples, glioma cells, and glioma tissue.